These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23434002)

  • 1. [About new treatments in thoracic oncology].
    Couraud S
    Rev Pneumol Clin; 2013 Apr; 69(2):63-4. PubMed ID: 23434002
    [No Abstract]   [Full Text] [Related]  

  • 2. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 3. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
    Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
    J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
    [No Abstract]   [Full Text] [Related]  

  • 4. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten lessons from EGFR.
    Nakanishi Y
    Respir Investig; 2014 May; 52(3):151-2. PubMed ID: 24853013
    [No Abstract]   [Full Text] [Related]  

  • 9. Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
    Azzoli CG
    Ann Surg Oncol; 2015 Oct; 22(11):3459-65. PubMed ID: 26215190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 11. Erlotinib: optimizing therapy with predictors of response?
    Goodin S
    Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
    [No Abstract]   [Full Text] [Related]  

  • 12. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.
    Lee CN; Chen HY; Liu HE
    J Clin Oncol; 2010 Mar; 28(7):e111-2. PubMed ID: 20008635
    [No Abstract]   [Full Text] [Related]  

  • 13. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
    Kuo YW; Wu SG; Ho CC; Shih JY
    J Thorac Oncol; 2010 Dec; 5(12):2039-40. PubMed ID: 21102267
    [No Abstract]   [Full Text] [Related]  

  • 14. Will lung cancer targeting hit its mark?
    Hampton T
    JAMA; 2005 Apr; 293(16):1963-4. PubMed ID: 15855415
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of lung cancer.
    Wang J; Qiu JH
    N Engl J Med; 2009 Dec; 361(25):2486; author reply 2487. PubMed ID: 20050214
    [No Abstract]   [Full Text] [Related]  

  • 17. Current status and study activity of lung cancer in Japan.
    Nukiwa T
    Respir Investig; 2014 Nov; 52(6):315-6. PubMed ID: 25453373
    [No Abstract]   [Full Text] [Related]  

  • 18. An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.
    Chan AW; Tong JH; Lo SH; To KF
    J Thorac Oncol; 2013 Dec; 8(12):e107-8. PubMed ID: 24389445
    [No Abstract]   [Full Text] [Related]  

  • 19. [KRAS status versus EGFR status in lung cancer therapy].
    Lacroix L; Besse B; Bidart JM; Bosq J
    Bull Cancer; 2009 Dec; 96 Suppl():S75-83. PubMed ID: 20034873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
    Fallet V; Ruppert AM; Poulot V; Lacave R; Belmont L; Antoine M; Cadranel J; Wislez M; Lavolé A
    J Thorac Oncol; 2012 Jun; 7(6):1061-3. PubMed ID: 22588159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.